NCT05699239View on ClinicalTrials.gov

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

PHASE2CompletedINTERVENTIONAL
Enrollment

326

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

December 26, 2023

Study Completion Date

December 26, 2023

Conditions
Hyperphosphatemia Patients on Hemodialysis
Interventions
DRUG

TS-172 10mg bid

oral administration of TS-172 10 mg bid

DRUG

TS-172 30mg bid

oral administration of TS-172 30 mg bid

DRUG

TS-172 60mg bid

oral administration of TS-172 60 mg bid

DRUG

TS-172 20mg tid

oral administration of TS-172 20 mg tid

DRUG

Placebo

oral administration of placebo

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY